Company intelligence / Profile preview

Tianjin Hemay Biotech

Tianjin Airport Economic Zone, Tianjin, Chinahemay.com.cn ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has several small molecule drugs in clinical development targeting autoimmune diseases and cancers. Lead asset Mufemilast has reached Phase III for plaque psoriasis and Behçet's syndrome; other assets are in various stages up to Phase III for oncology and immunology indications. Multiple patents granted globally.

Therapeutic areas: OncologyImmunologyDermatologyRheumatologyGastroenterology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

9 assets

sacibertinib

8 more assets in the full pipeline.

Request access →

Partnerships

Hainan HailingGanzhou Hemay PharmaceuticalXiajiang Hemei Pharmaceutical Co.Hainan General Sanyang Pharmaceutical Co.academic/government collaborations via national science projects.

Beyond the preview

Go deeper on Tianjin Hemay Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianjin Hemay Biotech.

Explore the full profile